Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
RATIONAL: Simmitecan is an anticancer ester prodrug, which involves activation to
chimmitecan. Chimmitecan，a novel CPT derivative, exhibited potent antitumor activities both
in vitro and in vivo by inhibiting topoisomerase I. Also exerted comparable effects on
topoisomerase I compared with topotecan and SN38 and possessed improved anticancer potency
and pharmacologic profiles, compared with the clinically available CPT analogues.
PURPOSE: to determine the maximum tolerated dose, the safety profile and pharmacokinetics of
Simmitecan.